Assertio (ASRT) Competitors

$23.32 +0.01 (+0.02%)

As of 03:48 PM Eastern

ASRT vs. ALLO, FDMT, AVTX, IMMX, and PROK

Should you buy Assertio stock or one of its competitors? MarketBeat compares Assertio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assertio include Allogene Therapeutics (ALLO), 4D Molecular Therapeutics (FDMT), Avalo Therapeutics (AVTX), Immix Biopharma (IMMX), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry.

How does Assertio compare to Allogene Therapeutics?

Assertio (NASDAQ:ASRT) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

In the previous week, Allogene Therapeutics had 2 more articles in the media than Assertio. MarketBeat recorded 11 mentions for Allogene Therapeutics and 9 mentions for Assertio. Allogene Therapeutics' average media sentiment score of 0.67 beat Assertio's score of -0.22 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio presently has a consensus target price of $22.65, indicating a potential downside of 2.89%. Allogene Therapeutics has a consensus target price of $8.07, indicating a potential upside of 277.99%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

49.0% of Assertio shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Assertio has higher revenue and earnings than Allogene Therapeutics. Assertio is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

Assertio has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Allogene Therapeutics	N/A	-57.07%	-41.63%

Summary

Allogene Therapeutics beats Assertio on 12 of the 16 factors compared between the two stocks.

How does Assertio compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Assertio. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 9 mentions for Assertio. 4D Molecular Therapeutics' average media sentiment score of 0.19 beat Assertio's score of -0.22 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

4D Molecular Therapeutics presently has a consensus target price of $29.88, suggesting a potential upside of 203.45%. Assertio has a consensus target price of $22.65, suggesting a potential downside of 2.89%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe 4D Molecular Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 5.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Assertio has higher revenue and earnings than 4D Molecular Therapeutics. Assertio is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.04	-$140.11M	-$2.57	N/A
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A

4D Molecular Therapeutics has a beta of 2.77, meaning that its stock price is 177% more volatile than the broader market. Comparatively, Assertio has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Assertio has a net margin of -34.94% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Assertio	-34.94%	-38.72%	-13.32%

Summary

4D Molecular Therapeutics beats Assertio on 12 of the 16 factors compared between the two stocks.

How does Assertio compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Avalo Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-77.91%	-61.78%
Assertio	-34.94%	-38.72%	-13.32%

In the previous week, Avalo Therapeutics had 9 more articles in the media than Assertio. MarketBeat recorded 18 mentions for Avalo Therapeutics and 9 mentions for Assertio. Avalo Therapeutics' average media sentiment score of 0.57 beat Assertio's score of -0.22 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Avalo Therapeutics currently has a consensus target price of $48.13, suggesting a potential upside of 154.29%. Assertio has a consensus target price of $22.65, suggesting a potential downside of 2.89%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Assertio has higher revenue and earnings than Avalo Therapeutics. Assertio is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	9,251.17	-$78.26M	-$5.73	N/A
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A

Avalo Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Assertio has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 5.7% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Avalo Therapeutics beats Assertio on 10 of the 16 factors compared between the two stocks.

How does Assertio compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Immix Biopharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Assertio has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Comparatively, 5.7% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immix Biopharma has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Assertio	-34.94%	-38.72%	-13.32%

In the previous week, Assertio had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 9 mentions for Assertio and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.36 beat Assertio's score of -0.22 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immix Biopharma currently has a consensus target price of $18.25, suggesting a potential upside of 81.23%. Assertio has a consensus target price of $22.65, suggesting a potential downside of 2.89%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Immix Biopharma has higher earnings, but lower revenue than Assertio. Immix Biopharma is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A

Summary

Immix Biopharma beats Assertio on 8 of the 15 factors compared between the two stocks.

How does Assertio compare to ProKidney?

ProKidney (NASDAQ:PROK) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

ProKidney has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Assertio has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 5.7% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Assertio has a net margin of -34.94% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-7,725.20%	N/A	-18.83%
Assertio	-34.94%	-38.72%	-13.32%

In the previous week, Assertio had 5 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Assertio and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.72 beat Assertio's score of -0.22 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ProKidney currently has a consensus target price of $7.40, indicating a potential upside of 334.02%. Assertio has a consensus target price of $22.65, indicating a potential downside of 2.89%. Given ProKidney's stronger consensus rating and higher probable upside, equities analysts clearly believe ProKidney is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Assertio has higher revenue and earnings than ProKidney. Assertio is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	578.40	-$68.99M	-$0.52	N/A
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A

Summary

ProKidney beats Assertio on 12 of the 17 factors compared between the two stocks.

Get Assertio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASRT vs. The Competition

Export

Metric	Assertio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$150.73M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-4.10	18.81	20.85	25.56
Price / Sales	1.48	279.58	543.57	72.25
Price / Cash	1,379.19	56.53	42.94	55.34
Price / Book	1.99	4.36	9.87	6.72
Net Income	-$30.38M	$72.19M	$3.55B	$333.62M
7 Day Performance	4.27%	-0.61%	-0.23%	0.35%
1 Month Performance	29.44%	0.34%	1.47%	4.00%
1 Year Performance	154.13%	46.24%	41.05%	36.32%

Assertio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASRT Assertio	1.7936 of 5 stars	$23.33 +0.0%	$22.65 -2.9%	+155.4%	$150.73M	$102.16M	N/A	20	News Coverage Earnings Report Analyst Forecast High Trading Volume
ALLO Allogene Therapeutics	3.4841 of 5 stars	$2.29 +0.2%	$8.44 +269.3%	+106.2%	$559.41M	$20K	N/A	310	Trending News Earnings Report
FDMT 4D Molecular Therapeutics	2.3526 of 5 stars	$10.38 -3.8%	$29.88 +187.9%	+219.6%	$543.14M	$88.24M	N/A	120	Earnings Report Analyst Revision Gap Up
AVTX Avalo Therapeutics	3.1612 of 5 stars	$20.01 -1.2%	$49.63 +148.0%	+439.4%	$534.63M	$60K	N/A	40	Earnings Report Analyst Forecast
IMMX Immix Biopharma	2.9216 of 5 stars	$9.79 -1.3%	$18.25 +86.5%	+429.8%	$534.03M	N/A	N/A	9	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASRT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assertio (ASRT) Competitors

ASRT vs. ALLO, FDMT, AVTX, IMMX, and PROK

How does Assertio compare to Allogene Therapeutics?

Summary

How does Assertio compare to 4D Molecular Therapeutics?

Summary

How does Assertio compare to Avalo Therapeutics?

Summary

How does Assertio compare to Immix Biopharma?

Summary

How does Assertio compare to ProKidney?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT vs. The Competition

Assertio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assertio (ASRT) Competitors

ASRT vs. ALLO, FDMT, AVTX, IMMX, and PROK

How does Assertio compare to Allogene Therapeutics?

Does the media favor ASRT or ALLO?

Do analysts recommend ASRT or ALLO?

Do insiders and institutionals have more ownership in ASRT or ALLO?

Which has better earnings and valuation, ASRT or ALLO?

Which has more volatility & risk, ASRT or ALLO?

Is ASRT or ALLO more profitable?

Summary

How does Assertio compare to 4D Molecular Therapeutics?

Does the media refer more to FDMT or ASRT?

Do analysts prefer FDMT or ASRT?

Do institutionals and insiders have more ownership in FDMT or ASRT?

Which has stronger earnings and valuation, FDMT or ASRT?

Which has more risk and volatility, FDMT or ASRT?

Is FDMT or ASRT more profitable?

Summary

How does Assertio compare to Avalo Therapeutics?

Is AVTX or ASRT more profitable?

Does the media refer more to AVTX or ASRT?

Do analysts rate AVTX or ASRT?

Which has preferable earnings & valuation, AVTX or ASRT?

Which has more volatility & risk, AVTX or ASRT?

Do insiders & institutionals have more ownership in AVTX or ASRT?

Summary

How does Assertio compare to Immix Biopharma?

Which has more volatility & risk, IMMX or ASRT?

Do insiders & institutionals have more ownership in IMMX or ASRT?

Is IMMX or ASRT more profitable?

Does the media refer more to IMMX or ASRT?

Do analysts rate IMMX or ASRT?

Which has preferable earnings & valuation, IMMX or ASRT?

Summary

How does Assertio compare to ProKidney?

Which has more volatility and risk, PROK or ASRT?

Do institutionals & insiders believe in PROK or ASRT?

Is PROK or ASRT more profitable?

Does the media prefer PROK or ASRT?

Do analysts rate PROK or ASRT?

Which has stronger earnings & valuation, PROK or ASRT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT vs. The Competition

Assertio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools